Persistence Market Research

Osteoporosis Drugs Market - Global Study on Osteoporosis Drugs - Asia
Pacific to Witness Highest Growth by 2022
Persistence Market Research
Global Osteoporosis Drugs Market Will

Reach US$14.8 Billion by 2022: Persistence
Market Research

Persistence Market Research Released New Market Report Global Market Study on Osteoporosis
Drugs: AsiaPacific to Witness Highest Growth by 2022, the global osteoporosis drugs market
is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand
at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
Browse
the
full
Osteoporosis
Drugs
Market
report
at
http://www.persistencemarketresearch.com/market-research/osteoporosis-drugs-market.asp
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric
population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high
among people aged 60 years and above. Moreover, increasing the prevalence of
osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and
increasing investment in drug discovery and development are also driving the growth of the
market. However, there are various side effects and complications associated with
osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the
stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits
the growth of the market.The osteoporosis drugs market is anticipated to grow from an
estimated US$11,226.1 Mn by the end of 2015 to account for US$14,786.7 Mn by 2022 at a
CAGR of 4.0% during the forecast period.
In North America, the prevalence of osteoporosis is high primarily due to increasing geriatric
population, growing obesity, and rising prevalence of lifestyle associated diseases in the
region. According to the National Osteoporosis Foundation, in 2013, approximately 54 million
people in the U.S. aged 50 years and above were affected by osteoporosis and low bone
mass. According to the U.S. Department of Health and Human Services, in the U.S.,
approximately 250,000 hip fractures are associated with osteoporosis.
In Europe, increasing aging population, changing lifestyles, and increasing consumer

awareness about osteoporosis care are driving the growth of the osteoporosis drug market.
According to the International Osteoporosis Foundation, approximately 5.5 million men and
22 million women suffered from osteoporosis in 2010. Moreover, according to International
Osteoporosis Foundation, approximately 27.5 million people in Europe suffered from
osteoporosis in 2010 and the number is expected to reach 33.9 Mn by 2030.

However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric
population and changing lifestyles in the region. Osteoporotic patients have a higher risk of
hip fractures, owing to a major cause of morbidity and mortality. According to the
International Osteoporosis Foundation, by 2050, approximately 50% of the worlds
osteoporosis hip fractures would occur in women in Asia. In addition, according to a study on
Epidemiology in Osteoporosis in Japan by the National Centre for Biotechnology Information,
in 2011, approximately 15 million people suffered from osteoporosis in Japan.
Request Sample Report at http://www.persistencemarketresearch.com/samples/2983
Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Merck & Co. Inc., Novartis AG, Amgen,
Inc., Actavis plc, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc. are some of the major
players of osteoporosis drugs market.
The osteoporosis drugs market is segmented as follows:
By drug type
Bisphosphonates
Parathyroid Hormone Therapy Drugs
Calcitonin
Selective Estrogen Receptors Modulators (SERMs)
RANK Ligand Inhibitors
By geography
North America
The U.S.
Europe
Germany

France
The U.K.
Asia
China
Japan
India
Rest of the World (RoW)
Market History:
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population
and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in
postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug
discovery and development are also driving the growth of the market. However, there are various side
effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel
syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of
osteoporosis drugs also inhibits growth of the market.
The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn in 2015 to
account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.North America is the
largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis
drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the
fastest growing type of osteoporosis drugs.
Bisphosphonates are the most commonly prescribed medication for treatment and prevention of
osteoporosis. The global bisphosphonates drugs market is expected to grow from an estimated
US$5,482.6 Mn in 2015 to US$7,342.2 Mn by 2022 at a CAGR of 4.3% during the forecast period.
Table of Content
Chapter 1 Preface 8

1.1 Report Description 8
1.2 Research Methodology 9
1.3 Assumptions 9
Chapter 2 Market Synopsis 10
Chapter 3 Porters Five Forces Analysis 11
3.1 Bargaining Power of Suppliers 11
3.2 Bargaining Power of Buyers 12
3.3 Threat of New Entrants 12
3.4 Threat of Substitutes 12
3.5 Intensity of Rivalry 13
Chapter 4 Industry Overview 14
4.1 Market Definition 14
4.2 Market Drivers 16
4.2.1 Rising geriatric population 16
4.2.2 Change in lifestyle impinging bone health 17
4.2.3 Increasing prevalence of osteoporosis in post-menopausal women 18
4.2.4 Increasing awareness about osteoporosis care 19
4.2.5 Increasing R&D investments in drug discovery and development 20

4.3 Impact Analysis of Market Drivers 20
4.4 Market Restraints 21
4.4.1 Side effects and complications associated with administration of osteoporosis
drugs 21
4.4.2 Patent expiration of osteoporosis drugs 22
4.5 Impact Analysis of Market Restraints 23
Chapter 5 Global Market Size and Forecast 24
Chapter 6 Market Size and Forecast by Drug Type 28
6.1 Bisphosphonates 28
6.2 Parathyroid Hormone Therapy Drugs 30
6.3 Calcitonin 32
6.4 Selective Estrogen Receptor Modulators (SERMs) 34
6.5 RANK Ligand Inhibitors (Denosumab) 36
Chapter 7 Market Size and Forecast by Geography 39
7.1 North America 39
7.2 Europe 41
7.3 Asia Pacific 44
Chapter 8 Competitive Scenario 48
8.1 Competitive Analysis 48

Chapter 9 Company Profiles 50

9.1 Eli Lilly and Company 50
9.1.1 Company overview 50
9.1.2 Products and services 50
9.1.3 Financial performance 51
9.1.4 Key developments 51
9.2 F. Hoffmann-La Roche Ltd 52
9.3 Merck & Co. Inc. 54
9.4 Novartis AG 56


9.5 Amgen, Inc. 58
9.5.1 Company Overview 58
9.5.2 Product and Services 58
9.5.3 Financial Performance 58
9.5.4 Recent Developments 59
9.6 Novo Nordisk A/S 60
9.7 Actavis plc 62

9.8 Pfizer, Inc 65

9.9 GlaxoSmithKline plc 67
9.10 Teva Pharmaceutical Industries Ltd. 69
List of Table
TABLE 1 Market snapshot: osteoporosis drugs market, 2015and 2022 10
TABLE 2 Drivers for osteoporosis drugs market: Impact analysis 20

TABLE 3 Patent expiration of various osteoporosis drugs 22

TABLE 4 Restraints for global osteoporosis drugs market: Impact analysis 23
TABLE 5 Global osteoporosis drugs market size, by region, 2012 2014 (US$ Mn) 24
TABLE 6 Global osteoporosis drugs market size, by region, 2015 2022 (US$ Mn) 25
TABLE 7 Global osteoporosis drugs market size, by type, 2012 2014 (US$ Mn) 26
TABLE 8 Global osteoporosis drugs market size, by type, 2015 2022 (US$ Mn) 27
TABLE 9 Risk reduction of fracture with bisphosphonates over 34 years 28
TABLE 10 Global bisphosphonates drugs market size, by region, 2012 2014 (US$ Mn) 29
TABLE 11 Global bisphosphonates drugs market size, by region, 2015 2022 (US$ Mn) 30
TABLE 12 Global parathyroid hormone therapy drugs market size, by region, 2012 2014
(US$ Mn) 31
TABLE 13 Global parathyroid hormone therapy drugs market size, by region, 2015 2022
(US$ Mn) 32
TABLE 14 Global calcitonin drugs market size, by region, 2012 2014 (US$ Mn) 33
TABLE 15 Global calcitonin drugs market size, by region, 2015 2022 (US$ Mn) 34
TABLE 16 Global SERMs drugs market size, by region, 2012 2014 (US$ Mn) 35
TABLE 17 Global SERMs drugs market size, by region, 2015 2022 (US$ Mn) 36
TABLE 18 Global RANK ligand inhibitors drugs market size, by region, 2012 2014 (US$ Mn)
37
10

TABLE 19 Global RANK ligand inhibitors drugs market size, by region, 2015 2022 (US$ Mn)
38
TABLE 20 North America osteoporosis drugs market size, by country, 2012 2014 (US$ Mn)
40
TABLE 21 North America osteoporosis drugs market size, by country, 2015 2022 (US$ Mn)
41
TABLE 22 Europe osteoporosis drugs market size, by country, 2012 2014 (US$ Mn) 43
TABLE 23 Europe osteoporosis drugs market size, by country, 2015 2022 (US$ Mn) 44
TABLE 24 Asia Pacific osteoporosis drugs market size, by country, 2012 2014 (US$ Mn) 46
TABLE 25 Asia Pacific osteoporosis drugs market size, by country, 2015 2022 (US$ Mn) 47
TABLE 26 Major products of Eli Lilly and Company 50
TABLE 27 Major products of F. Hoffmann-La Roche, Ltd. 52
TABLE 28 Major products of Merck & Co., Inc. 54
TABLE 29 Major products of Novartis AG 56
TABLE 30 Major products of Amgen, Inc. 58
TABLE 31 Major products of Novo Nordisk A/S 60
TABLE 32 Major products of Actavis plc 62
TABLE 33 Major products of Pfizer, Inc. 65
TABLE 34 Major products of GlaxoSmithKline plc 67
TABLE 35 Major products of Teva Pharmaceutical Industries Ltd. 69
11

List of Figure
FIG. 1 Osteoporosis drugs market: Porters five force analysis 11
FIG. 2 Risk factors for osteoporosis 14
FIG. 3 Prevention of osteoporosis 15
FIG. 4 Aging population in major regions, 2000 2050 (% share in total population) 17
FIG. 5 Decrease of bone mass with onset of menopause 19
FIG. 6 Global osteoporosis drugs market share, by region, by value, 2014 24
FIG. 7 Global osteoporosis drugs market share, by type, by value, 2014 26
FIG. 8 Global bisphosphonates drugs market share, by region, by value, 2014 29
FIG. 9 Global parathyroid hormone therapy drugs market share, by region, by value, 2014 31
FIG. 10 Global calcitonin drugs market share, by region, by value, 2014 33
FIG. 11 Global SERMs drugs market share, by region, by value, 2014 35
FIG. 12 Global RANK ligand inhibitors drug market share, by region, by value, 2014 37
FIG. 13 North Americaosteoporosis drugs market share, by country, by value, 2014 40
FIG. 14 Number of hip fracture cases in European Union member states, 2000 2050 42
FIG. 15 Number of vertebra fracture cases in European Union member states, 2000 2050
42
FIG. 16 Europe osteoporosis drugs market share, by country, by value, 2014 43
12

FIG. 17 Asia Pacific osteoporosis drugs market share, by country, by value, 2014 46
FIG. 18 Drug focus analysis of osteoporosis drugs market 48
FIG. 19 Revenue and net income of Eli Lilly and Company, 20122014 (US$ Mn) 51
FIG. 20 Sales and net income of F. Hoffmann-La Roche, Ltd., 20122014 (US$Mn) 53
FIG. 21 Sales and net income of Merck & Co., Inc., 20122014 (US$Mn) 55
FIG. 22 Net sales and net income of Novartis AG, 20122014 (US$Mn) 57
FIG. 23 Total revenue and net income of Amgen, Inc., 20122014 (US$Mn) 59
FIG. 24 Novo Nordisks net sales and net profit, 2012 2014 (US$ Mn) 61
FIG. 25 Net revenue and net income of Actavis plc, 20122014 (US$ Mn) 63
FIG. 26 Revenue and net income of Pfizer, Inc., 20122014 (US$Mn) 66
FIG. 27 Turnover and total profit attributable to stakeholders of GlaxoSmithKline plc, 2012
2014 (US$Mn) 68
FIG. 28 Net revenue and net income of Teva Pharmaceutical Industries Ltd., 20122014
(US$Mn) 70
About Us:
Persistence Market Research is a global market research firm specializing- syndicated research,
custom research, and consulting services
At Persistence Market Research (PMR), we are in the business of accelerating your business. As a fullservice market research firm, we stand committed to bringing more accuracy and speed to your business
decisions. From ready-to-purchase market research reports to customized global research solutions, our
engagement models are highly flexible without compromising on our deep-seated research values. Briefly
13

stated, our mission is to give you access to forecasts and trends analyses that put you on the path to
profitability.
PMRs Services Go Beyond Gleaning Data
Most enterprises believe that IT and databases are enough to make an accurate decision. While we do
not dispute that, consider this: How long does it take to make an accurate and strategic million-dollar
decision? We strive to deliver both even with demanding deadlines.
Contact Us:
Addie Thomes
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
14

Persistence Market Research

Caricato da

Informazioni sul documento

Descrizione originale:

Titolo originale

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Persistence Market Research

Caricato da

Copyright:

Formati disponibili

Osteoporosis Drugs Market - Global Study on Osteoporosis Drugs - Asia

Pacific to Witness Highest Growth by 2022